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5-Methylthioadenosine Modulates the Inﬂammatory
Response to Endotoxin in Mice and in Rat Hepatocytes
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M. Ujue Latasa,1 Shelly C. Lu,2 Jose´ M. Mato,1 Elena R. Garcı´a-Trevijano,1 and Matı´as A. Avila1
5-methylthioadenosine (MTA) is anucleosidegenerated fromS-adenosylmethionine (AdoMet)dur-
ing polyamine synthesis. Recent evidence indicates that AdoMetmodulates in vivo the production of
inﬂammatory mediators. We have evaluated the anti-inﬂammatory properties of MTA in bacterial
lipopolysaccharide (LPS) challenged mice, murine macrophage RAW 264.7 cells, and isolated rat
hepatocytes treated with pro-inﬂammatory cytokines. MTA administration completely prevented
LPS-induced lethality. The life-sparing effect ofMTAwas accompanied by the suppression of circu-
lating tumor necrosis factor- (TNF-), inducibleNO synthase (iNOS) expression, and by the stim-
ulation of IL-10 synthesis. These responses to MTA were also observed in LPS-treated RAW 264.7
cells. MTA prevented the transcriptional activation of iNOS by pro-inﬂammatory cytokines in iso-
latedhepatocytes, andthe inductionofcyclooxygenase2(COX2) inRAW264.7cells.MTAinhibited
the activation of p38 mitogen-activated protein kinase (MAPK), c-jun phosphorylation, inhibitor
kappaB alpha (IB) degradation, andnuclear factorB (NFB) activation, all ofwhich are signal-
ing pathways related to the generation of inﬂammatorymediators. These effectswere independent of
themetabolic conversionofMTA intoAdoMet and thepotential interactionofMTAwith the cAMP
signaling pathway, central to the anti-inﬂammatory actions of its structural analog adenosine. In
conclusion, these observations demonstrate novel immunomodulatory properties forMTA thatmay
be of value in themanagement of inﬂammatory diseases. (HEPATOLOGY 2004;39:1088–1098.)
Inﬂammatory reactions occur in response to a varietyof pathogenic insults, including microbial products,tissue injury, and tumor cells. The primary purpose of
this physiological reaction is to eliminate the pathogenic
insult and restore tissue integrity. However, when the
magnitude or the duration of this response exceeds certain
limits, consequences are always deleterious to the host.
Therapeutic strategies aimed at themodulation of inﬂam-
mation are thus of primary interest.
One of the most vigorous inﬂammatory responses is that
triggered by bacterial products, such as lipopolysaccharide
(LPS).1 In mammals, LPS elicits a potent reaction involving
the generation of numerous inﬂammatory mediators of di-
verse cellular origin such as cytokines, arachidonic acid me-
tabolites, reactive oxygen species, and nitric oxide (NO).2,3
Among these, tumor necrosis factor- (TNF-) is a pro-
inﬂammatory cytokine recognized as a central mediator of
endotoxemia and other inﬂammatory processes, being also a
key determinant in the induction of NO synthesis in re-
sponse to LPS.4,5 Systemic exposure to LPS is frequently
found in patients with liver cirrhosis, correlating with the
degree of liver failure.3 The liver plays a central role in clear-
ing LPS from the circulation and also responds to LPS, pro-
ducing inﬂammatory cytokines and mediators.3,6 In this
regard, multiple experimental evidence (animal models of
liver damage including cholinedeﬁciency,CCl4, and ethanol
administration) and clinical observations indicate that LPS,
mainly derived from the gastrointestinal tract, has an etiolog-
ical role in liver injury.3,6,7
Administration of S-adenosylmethionine (AdoMet;
also abbreviated as SAMe and SAM) in different experi-
Abbreviations: LPS, bacterial lipopolysaccharide; TNF-, tumor necrosis factor alpha;
AdoMet, S-adenosylmethionine; iNOS, inducible NO synthase; IL-10, interleukin 10;
MTA,5-methylthioadenosine;EMSA,electrophoreticmobility shiftassay;MTAP,5-meth-
ylthioadenosine phosphorylase; PKA, protein kinase A; COX2, cyclooxygenase 2; IB, in-
hibitorB alpha; NFB, nuclear factorB;MAPK,mitogen activated protein kinase.
From the 1Divisio´n de Hepatologı´a y Terapia Ge´nica, Departamento de Medicina In-
terna, CIMA,Universidad deNavarra, Pamplona, Spain; and 2Division of Gastroenterol-
ogy and Liver Diseases, USC-UCLA, Research Center for Alcoholic Liver and Pancreatic
Diseases, USC Liver Disease Research Center, USC School ofMedicine, Los Angeles, CA.
Received September 22, 2003; accepted January 11, 2004.
Supported by Plan Nacional de ID 2002-00168 from Ministerio de Educacio´n y
Ciencia; grants FIS 01/0712 and FIS PI020369 fromMinisterio de Sanidad y Consumo;
681/2000 from Gobierno de Navarra; ROI AA-12677 from the National Institute on
Alcohol Abuse andAlcoholism; R01AT1576 from theNationalCenter forComplementary
andAlternativeMedicine; grants C03/02 andG03/015 from Instituto de SaludCarlos III.
Funded, in part, by the agreement between FIMA and the VTE project CIMA.
H.H. and M.V.-R. contributed equally to this work. H.H. was supported by a
fellowship from Fundacion Ramon Acreces.
J.M.M., E.R.G.-T., and M.A.A. share senior authorship.
J.M.M.’s present address: CIC-Biogune, Zamudio 48710, Bizkaia, Spain.
Address reprint requests to: Elena R. Garcı´a-Trevijano, Ph.D., Divisio´n de
Hepatologı´a y Terapia Ge´nica, Departamento de Medicina Interna, FIMA, Fac-
ultad de Medicina, Universidad de Navarra, 31008 Pamplona, Spain. E-mail:
eruiz @ unav.es; fax: 34-948-425677, and Shelly C. Lu, MD, Keck School of
Medicine USC, HMR 415, 2011 Zonal Ave., Los Angeles, CA 90033. E-mail:
shellylu@usc.edu; fax: 323-442-3234.
Copyright © 2004 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/hep.20154
1088
mental models of liver injury has been shown to attenuate
tissue damage and to improve survival in patients.8–10 An
inﬂammatory component is a common denominator to
many of the hepatotoxic conditions in which AdoMet
alleviates liver injury,11–16 and there is increasing evidence
indicating that the modulation of such an inﬂammatory
response could be behind the beneﬁcial effects of
AdoMet. In this regard, it has been recently reported that
AdoMet inhibits LPS-induced TNF- production and
inducible NO synthase (iNOS) expression in vivo and
stimulates interleukin-10 (IL-10) production in macro-
phages.16–18 AdoMet displays a remarkable array of bio-
logical effects and is emerging as an important regulator of
many cellular responses, including gene expression, cell
proliferation, differentiation, and apoptosis; however, the
molecular mechanisms behind these effects are not com-
pletely known.19 AdoMet, synthesized from L-methio-
nine and ATP by the action of methionine
adenosyltransferases (MAT), is the main methyl-group
donor in methylation reactions, serves as a glutathione
precursor in the liver, and participates in the synthesis of
polyamines.19–21 During the synthesis of polyamines, de-
carboxylated AdoMet is converted into 5-methylthioad-
enosine (MTA);21 MTA can also be formed from the
spontaneous splitting of AdoMet under physiological
conditions.22 It has been observed that MTA retains
many of the effects of AdoMet, such as its antiproliferative
and antineoplastic actions, regulation of apoptosis, and
the prevention of CCl4-induced damage in rat liver.23–26
Consequently, it is conceivable that some of the effects of
AdoMet may be attributed to its conversion, either spon-
taneous or metabolic, into MTA. In the present work, we
have addressed the immunomodulatory potential of
MTA using a murine endotoxic shock model, as well as in
RAW 264.7 macrophages and isolated hepatocytes. Our
data demonstrate a potent anti-inﬂammatory proﬁle for
MTA.
Materials and Methods
Animal Experiments. Male C57BL6 mice (19–21 g
of weight) were from Harlan (Barcelona, Spain). Studies
were approved by the University of Navarra Committee
on Animal Care and satisﬁed National Institutes of
Health guidelines for humane treatment of animals. Mice
were injected with endotoxin (Salmonella typhimurium
LPS, Sigma, St. Louis, MO) dissolved in sterile, pyrogen-
free saline. Mice were given 15 mg/kg LPS intraperitone-
ally (ip). Blood was collected and sera obtained at
different times after LPS administration. Survival was
monitored up to 96 hours after injections. Where indi-
cated, a single dose of 96mol/kg ipMTA (Knoll Farma-
ceutici, Liscate, Italy) dissolved in dimethylsulfoxide (50
l/mouse) or vehicle was administered 30 minutes before
LPS injection. This dose of MTA has been previously
used inmodels of liver damage in rats.26 Nomodiﬁcations
in any of the parameters studied were observed in con-
trols. Survival experiments were performed three times
independently, all groups included 20 animals. Liver and
lung tissues were removed at the indicated time points
after treatments, snap-frozen in liquid nitrogen, and
stored at –80°C until analysis.
Cell Culture. Murine macrophage-like RAW 264.7
cells and human A549 lung carcinoma cells were from the
American Type Culture Collection (ATCC). Mouse
Kupffer cells were isolated as described previously.27 All
cells were cultured in Dulbecco’s Modiﬁed Eagle Me-
dium (Life Technologies, Paisley, UK) supplemented
with 10% fetal bovine serum, 2 mmol/L glutamine and
antibiotics (Life Technologies). Rat hepatocytes were iso-
lated from male Wistar rats (200 g of weight) by collage-
nase perfusion and cultured in Minimum Essential
Medium (Life Technologies) supplemented with 10% fe-
tal bovine serum, 2 mmol/L glutamine and antibiotics as
described previously.18 Cell viability was measured by
Trypan blue exclusion. No signiﬁcant differences were
observed between controls and any of the treatments.
Treatments were performed for the indicated periods
of time with 500 mol/L MTA, unless otherwise stated,
(30 minutes before LPS, 1g/mL, or cytokines) or with a
mixture of pro-inﬂammatory cytokines (CM): human re-
combinant interleukin 1 and TNF- (100 UI/mL each)
(Genzyme, Boston, MA).
Cytokine Measurements. TNF- and IL-10 concen-
trations in serum and conditioned media were measured
using enzyme-linked immunosorbent assay (ELISA) assay
kits from BD Biosciences (San Diego, CA) and Biosource
International (Camarillo, CA), respectively.
RNA Extraction and Northern Blot Analysis. Total
RNA extraction and Northern blot analysis were carried
out as reported previously.24 The iNOS probe has been
described,18 and the mouse TNF- cDNA probe was
generated by RT-PCR using the primers 5-GAGTGA-
CAAGCCTGTAGCCC-3 and 5-CCCTTCTCCAGC-
TGGAAGAC-3. Blots were hybridized with an 18S rRNA
probe as loading control.
Immunoblot Analysis. Tissues and cells were homog-
enized and Western blot analyses were performed as de-
scribed previously.18,24 Antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Equal loading was dem-
onstrated with an anti-actin polyclonal antibody (Calbio-
chem, Darmstad, Germany).
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Preparation of Nuclear Protein Extracts and Elec-
trophoretic Mobility Shift Assay (EMSA). Nuclear
protein extraction from hepatocytes and binding reac-
tions were as described previously.18 DNA-protein com-
plexes were resolved by electrophoresis on 4%
polyacrylamide gels. The oligonucleotides used have been
described.18
Transient Transfection of Rat Hepatocytes in Cul-
ture. Transfections were performed with 6.5 g of the
reporter plasmid pGL3NOS-8.3 (kindly provided byDr.
JoelMoss, NIH, Bethesda,MD), which harbors 8.3 kb of
human iNOS promoter,28 using the Tfx50 reagent (Pro-
mega, Madison, WI). After 36 hours, medium was
changed and cells were pretreated with MTA. CM treat-
ment was carried out for 24 hours, then cells were har-
vested and luciferase activity measured. Transfection
efﬁciency was determined by cotransfection with the plas-
mid pRL-TK (1g) (Promega). Renilla luciferase activity
was measured using the Dual-Luciferase Reporter Assay
System (Promega).
Determination of Nitrite Levels. NO production
was measured as the accumulation of nitrite in culture
medium after 24 hours of the onset of treatments as de-
scribed previously.18
Statistics. Data are the means SEM of at least three
independent experiments performed in triplicate. Repre-
sentative blots are shown. Statistical signiﬁcance was esti-
mated with Student’s t test. A P value of less than .05 was
considered signiﬁcant.
Results
Effect of MTA on LPS-Induced Lethal Shock in
Mice. Injection of LPS resulted in a 48-h survival rate of
only 10%. In contrast, pretreatment with a single dose of
MTA granted complete protection (100% survival rate at
48 hours, and no animal died thereafter for a total fol-
low-up time of 96 h; Fig. 1).
Large quantities of NO, derived from the high capacity
iNOS, are generated during Endotoxemia.29 We deter-
mined the levels of iNOS protein in the lungs and liver of
mice treated with LPS. iNOS expression was potently
induced in both organs (Fig. 2), while pretreatment with
a single dose of MTA blunted this effect.
We measured the levels of circulating TNF- 90 min-
utes after LPS administration in mice that had been pre-
treated or not with MTA. Figure 3A shows that MTA
completely prevented the elevation of TNF- in serum.
We also observed an increase in circulating IL-10 levels
after LPS administration (Fig. 3B). Pretreatment with
MTA resulted in a signiﬁcant augmentation of LPS-in-
duced IL-10 (Fig. 3B).
MTA Modulates the Response of RAW 264.7 Mac-
rophages to LPS. We next wanted to know if these sys-
temic responses to MTA administration could be
accounted for by the direct action of MTA on LPS target
cells. RAW 264.7 cells were pretreated with increasing
concentrations ofMTA, treatedwith LPS for 6 hours, and
TNF- levels were determined in conditioned media.
Figure 4A shows how MTA dose-dependently inhibited
TNF- production. To gain insight into the mechanism
of action of MTA, TNF- mRNA levels were measured.
Figure 4B shows howMTA reduced the steady-state levels
of TNF-mRNA in RAW 264.7 cells at all times tested.
We examined the effect of MTA on LPS-induced
IL-10 production by RAW 264.7 cells. Figure 4C shows
howMTA treatment resulted in a dose-dependent poten-
tiation of LPS-induced IL-10 levels.
Fig. 1. MTA treatment prevents LPS-induced death in mice. Mice were
injected with a single dose of MTA or vehicle followed 30 minutes later
by a lethal dose of LPS.
Fig. 2. MTA prevents the induction of iNOS gene expression in the liver
and lungs of LPS-treated mice. Mice (n  6 per group) were injected a
single dose of MTA or vehicle, followed 30 minutes later by a dose of
LPS. Six hours later, mice were killed. iNOS protein levels were deter-
mined in liver and lung by Western blotting.
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We next examined if the induction of iNOS by LPS
could be modulated by MTA in RAW 264.7 and Kupffer
cells. Figure 5A shows that MTA attenuated LPS-medi-
ated iNOS protein induction. This effect resulted in re-
duced production of NO, as demonstrated by nitrite
levels in RAW 264.7 culture medium (1.8  0.4 nmol/
106 cells in controls vs. 66.8 3.3 in LPS and 42.9 2.3
in MTA plus LPS; P  .05).
Cyclooxygenase 2 (COX2) expression can be induced
by LPS and pro-inﬂammatory cytokines in macro-
phages.30,31 We measured COX2 protein levels in RAW
264.7 cells treated with LPS or CM. Figure 5B shows that
MTA attenuated the induction of COX2 by LPS and
completely abolished the effect of CM.
iNOS and TNF- induction by LPS are dependent on
the NF-B pathway, which involves the degradation of
inhibitor-B (IB).29,32 In RAW 264.7 cells, we observed
that LPS dramatically reduced IB contents between 15
and 30 minutes after its addition, and this response was
attenuated by MTA (Fig. 6A).
Activation of the p38mitogen-activated protein kinase
(MAPK) cascade is an important step in the production of
pro-inﬂammatory cytokines and the induction of COX2
by LPS in macrophages.31,33 MTA attenuated the time-
dependent activation of this kinase in RAW 264.7 cells,
while the total cellular levels of p38 MAPK were not
affected (Fig. 6B). LPS activates the transient phosphor-
ylation of c-jun in macrophages, which is required for the
transcriptional activation of COX2.31 Accordingly, we
observed that LPS treatment of RAW 264.7 cells elicited
the phosphorylation of c-jun (Fig. 6C). This effect was
completely prevented by MTA (Fig. 6C).
MTA Modulates the Response of Hepatocytes to
CM. We evaluated whether MTA could modulate the
response of hepatocytes to pro-inﬂammatory cytokines.
Figure 7A shows that MTA dose-dependently reduced
iNOS mRNA levels induced after 3 hours of CM stimu-
lation. The same response was observed in isolated mouse
hepatocytes (data not shown). This resulted in decreased
NO production, as demonstrated by nitrite levels in cul-
ture medium (7.2 1.6 nmol/106 cells vs. 83.3 7.2 in
CM and 43.3 7.8 in CM plus MTA; P  .05).
Induction of iNOS expression in hepatocytes results
from enhanced iNOS gene transcription.29,32 We tested if
MTA could modulate CM-mediated transactivation of
iNOS promoter by CM. For this purpose, hepatocytes
were transfected with a human iNOS promoter-luciferase
reporter construct. MTA treatment reduced the levels of
luciferase activity induced byCM (Fig. 7B). Empty vector
activity was not affected by any stimuli (not shown).
Given the central role played by NF-B in cytokine-me-
diated induction of iNOS expression,29,32 we studied the
effect of MTA on NF-B binding activity in hepatocytes
by EMSA. Figure 7C shows that CM-mediated stimula-
tion of NF-B binding was inhibited by MTA. Complex
speciﬁcity was demonstrated by competition assays with
excess unlabeled NF-B consensus or mutated oligonu-
cleotides (not shown). Furthermore, CM-elicited degra-
dation of IB protein was attenuated by MTA (Fig.
7D).
MTA Effects Are Not Mediated Through Its Con-
version Into AdoMet. We have previously reported that
AdoMet inhibits CM-mediated induction of iNOS ex-
pression in rat hepatocytes.18 MTA can be converted to
methionine through the methionine salvage pathway so
that MTA addition to cells may raise the AdoMet
pool.21,22 We observed that MTA inhibition of LPS-in-
duced TNF- production by RAW 264.7 cells was pre-
served in the presence of cycloleucine, an inhibitor of
MAT activity34 (Fig. 8A). Cycloleucine signiﬁcantly re-
duced cellular AdoMet contents without affecting viabil-
ity (not shown). This suggests AdoMet is not the
Fig. 3. MTA inhibits TNF- and stimulates IL-10 production in LPS-
treated mice. Mice (n  6 per group) were treated with a single dose of
MTA or vehicle 30 minutes before a dose of LPS. (A) Circulating TNF-
levels 90 minutes after LPS injection. *P  .01 compared to controls;
**P .01 compared to LPS. (B) Circulating IL-10 levels at the indicated
time points after LPS administration. *P  .05 compared to controls.
**P  .05 compared to LPS.
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mediator of MTA’s effect. Additional evidence for the
AdoMet-independent effects of MTA was obtained in
A549 cells. These cells lack MTA phosphorylase
(MTAP), and thus are not able to utilize MTA as a pre-
cursor for AdoMet.35 MTA signiﬁcantly reduced iNOS
protein levels induced by LPS plus TNF- in A549 cells
(Fig. 8B).
MTA Effects Are Independent of the cAMP-PKA
Pathway. MTA interacts with adenosine purinergic re-
ceptors.36 Elevation of intracellular cAMP levels, and the
cAMP-PKA pathway, is central to the anti-inﬂammatory
effects of adenosine.37 As previously reported, the cAMP-
inducing agent forskolin downregulated LPS-induced
TNF- production, while H89 (a PKA inhibitor)
strongly potentiated this effect in RAW 264.7 cells38,39
(Fig. 9A). In the presence of MTA, the effect of forskolin
on TNF- was enhanced, while that of H89 was abol-
ished (Fig. 9A). We also tested the effect of PKA inhibi-
tion on the potentiation by MTA of LPS-induced IL-10
production. In the presence ofH89, the stimulatory effect
of MTA on IL-10 production was preserved (Fig. 9B).
Discussion
We have evaluated the anti-inﬂammatory properties of
the naturally occurring nucleoside MTA. In a model of
acute systemic inﬂammation induced by LPS administra-
tion tomice, we observed thatMTA completely protected
from LPS-induced death. One of the hallmarks of LPS-
induced systemic toxicity is the activation of iNOS gene
expression and the massive NO production in diverse
cellular backgrounds, a systemic response implicated in
the lethality of sepsis.29,40 We observed that the induction
of iNOS was signiﬁcantly attenuated by MTA in the liver
and lungs of LPS-treatedmice. TNF- is an early-released
cytokine recognized as a central mediator of endotoxemia
and systemic inﬂammation, which signiﬁcantly contrib-
utes to the activation of iNOS gene expression.4 In this in
Fig. 4. MTA inhibits LPS-induced TNF- production and potentiates the effect of LPS on IL-10 production in RAW 264.7 cells. Cells (105/ well)
were pretreated with MTA and then with LPS. (A) TNF- concentrations in conditioned media after 6 hours of LPS treatment in the presence of MTA.
*P .05, **P .01 compared to LPS. (B) Cells were pretreated or not with MTA and then with LPS. TNF- mRNA levels were measured by Northern
blotting. (C) IL-10 concentrations in conditioned media from cells treated with MTA and LPS for 18 hours. a P  .05 compared to control, b P 
.01 compared to LPS alone, c P  .01 compared to LPS alone, and P  .05 compared to LPS plus MTA at 300 mol/L.
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vivo model, we show that MTA markedly reduced circu-
lating TNF- levels. This action of MTA may be relevant
to its life-sparing effect, because the production of TNF-
is thought to be central in the mortality of endotox-
emia.4,41 Moreover, we also observed that the production
of the anti-inﬂammatory cytokine IL-10 was potently
stimulated by MTA treatment. IL-10 is an important
component of the endogenous response of the organism
to modulate the extent of inﬂammation, inhibiting the
synthesis of cytokines such as TNF-, and NO produc-
tion by macrophages.19,42
We have examined whether these in vivo responses
could be mediated by the direct interaction of MTA
with target inﬂammatory cells. Our results show that
MTA inhibited LPS-induced TNF- production and
iNOS gene expression, while it potentiated the release
of IL-10 in RAW 264.7 cells. Furthermore, we also
observed that LPS and CM-induced COX2 expression,
an enzyme that signiﬁcantly contributes pro-inﬂam-
matory mediators such as prostaglandin E230 was also
down-regulated by MTA. These observations suggest
that a similar response might occur in vivo in Kupffer
Fig. 5. MTA inhibits the effects of LPS and CM in RAW 264.7 and Kupffer cells. (A) Cells were pretreated with MTA and then LPS was added to
cultures. iNOS protein levels were determined by Western blotting after 6 hours or 20 hours for Kupffer cells. RAW 264.7 cells upper panel, *P 
.05 compared to LPS, **P  .05 compared to MTA 250 mol/L. Kupffer cells lower panel, *P  .05 compared to LPS. (B) RAW 264.7 cells were
pretreated or not with MTA (500 mol/L) and then with CM (upper panel) or LPS (lower panel) for 18 hours. COX2 expression was determined by
Western blotting. *P  .01 compared to CM or LPS alone.
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cells and alveolar macrophages. Taken together, these
effects indicate that MTA can directly modify the cy-
tokine and pro-inﬂammatory mediators balance to-
wards an anti-inﬂammatory proﬁle.
We also observed that MTA inhibits iNOS expres-
sion in rat hepatocytes stimulated by a mixture of pro-
inﬂammatory cytokines. The role of NO production in
sepsis is controversial, and inhibition of NO produc-
tion has been shown to have both detrimental and
beneﬁcial effects on animal survival and organ dam-
age,5 while, as previously mentioned, LPS-induced
mortality is attenuated in iNOS-deﬁcient mice.40 It
seems that excessive NO production, especially when
accompanied by reactive oxygen species, may have
detrimental consequences.5 Collectively, these effects
suggest that the anti-inﬂammatory action of MTA may
be two-fold, ﬁrst regulating the production of cyto-
kines by inﬂammatory cells and second attenuating the
effect of these cytokines on their cellular targets, such
as hepatocytes and macrophages.
MTA is structurally related to adenosine and is able to
interact with adenosine purinergic receptors.36 Adenosine
receptor agonists are known for their potent anti-inﬂam-
matory effects.37,43 Signaling of these effects is mainly
attributed to the activation of adenosine A2A receptors
and the elevation of cAMP levels.37 In this regard, it is
known that MTA is able to increase cellular cAMP lev-
els.44 Our data showed that MTA effects on the produc-
Fig. 6. Effect of MTA on IB protein levels, p38 MAPK, and c-jun phosphorylation in LPS-treated RAW 264.7 cells. Cells were pretreated with
MTA and then with LPS for different periods of time. (A) IB protein levels as determined by Western blotting. *P  .05 compared to LPS alone.
(B) Phosphorylation of p38 MAPK was monitored using a speciﬁc anti-phospho-p38 MAPK antibody by Western blotting. Lower panel shows total
cellular contents of p38 MAPK protein. (C) Phosphorylation of c-jun after 1 hour of treatment with LPS was monitored using an anti-phospho c-jun
(Ser-63) antibody by Western blotting. * and **P  .01 compared to control and to LPS, respectively.
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tion of TNF- and IL-10 were preserved in the presence
of H89, suggesting that changes in cellular cAMP levels
were not behind these actions of MTA. Nevertheless, the
interaction of MTA with other adenosine receptors that
convey cAMP-independent anti-inﬂammatory signals,
such as the A3 receptors, cannot be discarded.45
In vivo MTA can be metabolized only by MTAP to
yield adenine and 5-methylthioribose-1-phosphate.
This is the ﬁrst step in the methionine salvage route,
ultimately leading to the conversion of MTA into me-
thionine and subsequently into AdoMet.21 AdoMet
displays a wide array of cellular effects, observed both
in cultured cells and in vivo, including the reduction of
TNF- levels and iNOS expression and the stimula-
tion of IL-10 production.11,20 Hence, it was important
to know to what extent the anti-inﬂammatory actions
of MTA could be attributed to its conversion into
AdoMet. We present evidence suggesting that at least
some of these effects of MTA are independent from
AdoMet synthesis. The opposite situation, namely the
conversion of AdoMet into MTA, is also possible in
vivo. Our present observations suggest that some of the
reported effects of AdoMet related to the modulation
of the inﬂammatory response may be partly mediated
through its transformation into MTA.
The molecular bases of MTA effects are likely to be
multifaceted. Signal transduction through NF-B path-
way is a critical step in macrophage activation leading to
increased TNF- expression and to the induction of
iNOS in inﬂammatory cells and hepatocytes.3,29,46 More-
over, increased NF-B binding has been inversely corre-
lated with survival in septic patients.46 In agreement with
previous observations carried out in 70Z/3 cells,47 we ob-
served that MTA inhibits the DNA binding activity of
Fig. 7. Effect of MTA on the activation of iNOS gene expression and NFB transcription factor in rat hepatocytes stimulated with CM. (A)
Hepatocytes were pretreated with increasing concentrations of MTA and then stimulated with CM for 3 hours. iNOS mRNA levels were determined
by Northern blotting. (B) Hepatocytes were transfected with the pGLNOS-8.3 plasmid harboring the luciferase gene under the control of human iNOS
promoter. After transfection, cells were pretreated or not with MTA and then with CM for 24 hours. *P  .05 compared to controls, **P  .05
compared to CM. (C) Effect of MTA on CM-induced NFB DNA binding activity. Nuclear extracts were obtained from hepatocytes treated with CM and
MTA as indicated and analyzed by EMSA with a consensus NFB oligonucleotide. (D) Hepatocytes were treated with CM and MTA as indicated. IB
protein levels were determined by Western blotting. *P  .05 compared to CM alone.
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this transcription factor in cytokine-stimulated hepato-
cytes. Inducers of NF-B stimulate the phosphorylation,
subsequent ubiquitination, and degradation of IB, re-
leasing the NF-B proteins that translocate to the nucleus
and regulate gene transcription.3,29 Now, we show that
MTA partially prevents IB degradation and accelerates
its resynthesis. These results contribute to explain the at-
tenuation by MTA of cytokine-induced iNOS promoter
activity in cultured rat hepatocytes and the upregulation
iNOS and TNF- in LPS-treated RAW 264.7 macro-
phages.
MTA is known to have direct inhibitory effects on
protein kinases.48 We observed that LPS-mediated activa-
tion of p38 MAPK and c-jun phosphorylation in RAW
264.7 cells were inhibited byMTA. These signaling path-
ways play an important role in the activation of TNF-
and COX2 gene expression by endotoxin;31,33 conse-
quently, their interference by MTA can signiﬁcantly con-
tribute to the observed effects of this nucleoside. Finally,
it should also be considered that MTA is a well-known
inhibitor of protein methyltransferases.47 Protein methyl-
ation is emerging as a regulatory mechanism in cell sig-
naling, including inﬂammation-related signaling
pathways triggered by LPS,49 being in close interaction
with protein phosphorylation.50 Crosstalk between these
two signal transduction mechanisms could be modulated
by MTA.
In summary, we have uncovered novel biological ef-
fects of MTA supporting a role for this metabolite in the
modulation of the acute inﬂammatory response. Our ob-
servations may bear signiﬁcance to other inﬂammatory
processes, such as CCl4-induced liver damage in which
factors like TNF- and IL-10 play a role in the progres-
sion of the disease, and where MTA administration is
beneﬁcial.28 Finally, given the central role that endotox-
emia and pro-inﬂammatory cytokines play in the patho-
genesis of alcoholic liver injury and other disease processes
such as arthritis, it may be worthwhile to examine the
effect of MTA in these diseases.
Fig. 8. MTA mediated inhibition of TNF- production and iNOS ex-
pression is independent from its conversion into AdoMet. (A) RAW 264.7
cells were treated with 20 mmol/L cycloleucine for 12 hours and MTA
before LPS. TNF- levels in conditioned media after 6 hours of treatment.
*P  .01 compared to controls, **P  .01 compared to LPS. (B) A549
cells were pretreated with MTA, and then with LPS plus TNF- (5 ng/mL)
for 24 hours. iNOS protein levels were determined by Western blotting.
Fig. 9. MTA effects on TNF- and IL-10 production by RAW 264.7 cells are independent from the cAMP-PKA pathway. (A) Cells were pretreated
with MTA, forskolin 1 mol/L or H89 1 mol/L for 30 minutes, then were stimulated with LPS. TNF- concentrations in conditioned media 6 hours
later. a P  .05 compared to control, b P  .05 compared to LPS, c P  .01 compared to LPS, d P  .01 compared to forskolin/LPS, e P 
.01 compared to LPS, f P .01 compared to LPS/H89. (B) Cells were treated with MTA in the presence or absence of H89 (1 mol/L) for 30 minutes
and then with LPS as indicated. IL-10 concentrations in conditioned media after 18 hours. a P  .05 compared to control, b P  .01 compared
to LPS, c P  .01 compared to LPS.
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